<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MOXIFLOXACIN HYDROCHLORIDE</span><br/>(mox-i-flox'a-sin)<br/><span class="topboxtradename">Avelox, </span><span class="topboxtradename">Vigamox<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg tablets/injection; 0.5% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Moxifloxacin is a synthetic broad-spectrum antibiotic belonging to the fluoroquinolone class of drugs. It is bactericidal
         against gram-positive and gram-negative organisms. It inhibits topoisomerase II and IV (DNA gyrase) required for DNA replication,
         transcription, repair, and recombination of bacterial DNA.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is effective against <i>Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia
            pneumoniae,</i> and <i>Mycoplasma pneumoniae,</i> as well as other microbes.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia,
         skin and skin structure infections, bacterial conjunctivitis, complicated skin infections.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to moxifloxacin or other quinolones; moderate to severe hepatic insufficiency; syphilis; pregnancy (category
         C); lactation; patients with history of prolonged QT<sub>C</sub> interval on ECG, history of ventricular arrhythmias, atrial fibrillation, hypokalemia, bradycardia, acute myocardial ischemia,
         acute MI, patients receiving Class IA or Class III antiarrhythmic drugs; tendon pain; viral infection; torsade de pointes;
         ocular preparation use in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CNS disorders; cerebrovascular disease, colitis, diarrhea, GI disease; diabetes mellitus; mild or moderate heart insufficiency;
         myasthenia gravis; seizure disorder; sunlight (UV) exposure.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, Community-Acquired Pneumonia, Skin Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. <small>x</small> 510 d<br/><br/><span class="indicationtitle">Complicated Skin Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg q.d. <small>x</small> 721 d<br/><br/><span class="indicationtitle">Bacterial Conjunctivitis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Ophthalmic</span> &gt;<i>1 y,</i> 1 drop in affected eye(s) t.i.d. <small>x</small> 7 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Do not administer to persons with QT<sub>c</sub> prolongation, hypokalemia, or those receiving Class IA or Class III antiarrhythmic drugs.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Avelox (400 mg) is supplied in ready-to-use 250 mL IV bags. No further dilution is necessary.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 60 min. AVOID RAPID OR BOLUS DOSE.  
               </p>
</td>
</tr>
</table><span class="adminroutetype">Oral</span><br/><ul>
<li>Administer at least 4 h before or 8 h after multivitamins containing iron or zinc, or antacids containing magnesium, calcium,
            aluminum, or sucralfate.
         </li>
<li>Store at 15°30° C (59°86° F); protect from high humidity.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, headache, peripheral neuropathy. <span class="typehead">GI:</span> Nausea, diarrhea, abdominal pain, vomiting, taste perversion, abnormal liver function tests, dyspepsia. <span class="typehead">Musculoskeletal:</span> Tendon rupture, cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Iron,</b>
<b>zinc,</b>
<span class="classification">antacids</span>, <b>aluminum,</b>
<b>magnesium,</b>
<b>calcium,</b>
<b>sucralfate</b> decrease absorption; <b>atenolol,</b>
<b>erythromycin,</b>
<span class="classification">antipsychotics</span>, <span class="classification">tricyclic antidepressants</span>, <b>quinidine,</b>
<b>procainamide,</b>
<b>amiodarone,</b>
<b>sotalol</b> may cause prolonged QT<sub>C</sub> interval. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed, 90% bioavailable. <span class="typehead">Steady State:</span> 3 d. <span class="typehead">Distribution:</span> 50% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Unchanged drug: 20% in urine, 25% in feces; metabolites: 38% in feces, 14% in urine. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness indicated by clinical improvement of infection.</li>
<li>Monitor for and notify physician immediately of adverse CNS effects.</li>
<li>Notify physician immediately for S&amp;S of hypersensitivity (see Appendix F).</li>
<li>Lab tests: C&amp;S before initiation of therapy and baseline serum potassium with history of hypokalemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Exercise care in timing of consumption of vitamins and antacids (see <small>ADMINISTRATION</small>).
         </li>
<li>Drink fluids liberally, unless directed otherwise.</li>
<li>Increased seizure potential is possible, especially when history of seizure exists.</li>
<li>Stop taking drug and notify physician if experiencing palpitations, fainting, skin rash, severe diarrhea, ankle/foot pain,
            agitation, insomnia.
         </li>
<li>Avoid engaging in hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>